| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | THEA |
| Uniprot No | Q8WXI4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-607 aa |
| 活性数据 | MIQNVGNHLR RGLASVFSNR TSRKSALRAG NDSAMADGEG YRNPTEVQMS QLVLPCHTNQ RGELSVGQLL KWIDTTACLS AERHAGCPCV TASMDDIYFE HTISVGQVVN IKAKVNRAFN SSMEVGIQVA SEDLCSEKQW NVCKALATFV ARREITKVKL KQITPRTEEE KMEHSVAAER RRMRLVYADT IKDLLANCAI QGDLESRDCS RMVPAEKTRV ESVELVLPPH ANHQGNTFGG QIMAWMENVA TIAASRLCRA HPTLKAIEMF HFRGPSQVGD RLVLKAIVNN AFKHSMEVGV CVEAYRQEAE THRRHINSAF MTFVVLDADD QPQLLPWIRP QPGDGERRYR EASARKKIRL DRKYIVSCKQ TEVPLSVPWD PSNQVYLSYN NVSSLKMLVA KDNWVLSSEI SQVRLYTLED DKFLSFHMEM VVHVDAAQAF LLLSDLRQRP EWDKHYRSVE LVQQVDEDDA IYHVTSPALG GHTKPQDFVI LASRRKPCDN GDPYVIALRS VTLPTHRETP EYRRGETLCS GFCLWREGDQ LTKCCWVRVS LTELVSASGF YSWGLESRSK GRRSDGWNGK LAGGHLSTLK AIPVAKINSR FGYLQDT |
| 分子量 | 68.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人THEA蛋白的虚构参考文献示例(仅供格式参考)：
1. **文献名称**：*Optimized Expression and Purification of Recombinant Human THEA Protein in E. coli*
**作者**：Smith, J.R., et al.
**摘要**：研究通过大肠杆菌表达系统优化重组THEA蛋白的产量，筛选高效启动子与纯化标签，最终获得高纯度活性蛋白并验证其酶学稳定性。
2. **文献名称**：*Structural Analysis of THEA Protein Reveals Its Role in Cellular Signal Transduction*
**作者**：Li, X., & Wang, H.
**摘要**：通过X射线晶体学解析THEA蛋白的三维结构，阐明其与细胞膜受体结合的机制，为靶向药物设计提供结构基础。
3. **文献名称**：*Industrial Applications of Recombinant THEA Protein in Biocatalysis*
**作者**：García, M., et al.
**摘要**：评估THEA蛋白在工业催化中的潜力，证明其耐高温及有机溶剂特性适用于生物燃料合成，并实现规模化生产。
4. **文献名称**：*THEA Protein as a Therapeutic Target for Neurodegenerative Diseases*
**作者**：Chen, T., et al.
**摘要**：发现THEA蛋白可抑制异常蛋白聚集，在阿尔茨海默病模型中减轻神经元损伤，提出其作为神经保护剂的应用前景。
---
注：以上内容为模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索。若“THEA蛋白”名称有误，请提供更多背景信息以便精准查询。
**Background of Recombinant Human THEA Protein**
Recombinant human THEA (hypothetical acronym for a therapeutic or functional protein) is a lab-engineered protein produced through genetic engineering techniques. Typically, such proteins are designed by cloning the human gene encoding THEA into expression vectors, which are then introduced into host systems like *E. coli*, yeast, or mammalian cells (e.g., CHO cells) for large-scale production. This approach ensures high purity, consistency, and scalability compared to isolating the protein from natural sources.
THEA protein is hypothesized to play roles in specific biological pathways, such as cellular signaling, enzyme regulation, or immune modulation, depending on its structural and functional characteristics. Its recombinant form may include modifications (e.g., fusion tags, codon optimization) to enhance stability, solubility, or bioactivity.
Research on recombinant THEA focuses on therapeutic applications, including targeted drug delivery, treatment of genetic disorders, or as a diagnostic biomarker. It also serves as a tool in mechanistic studies to decode protein interactions or disease mechanisms. Safety and efficacy profiles are rigorously validated preclinically, aligning with biopharmaceutical standards.
Overall, recombinant THEA exemplifies advancements in biomanufacturing, bridging molecular biology and clinical innovation to address unmet medical needs.
×
